CN103965363A - 与pd-1和vegf高效结合的融合蛋白、其编码序列及用途 - Google Patents
与pd-1和vegf高效结合的融合蛋白、其编码序列及用途 Download PDFInfo
- Publication number
- CN103965363A CN103965363A CN201310046985.7A CN201310046985A CN103965363A CN 103965363 A CN103965363 A CN 103965363A CN 201310046985 A CN201310046985 A CN 201310046985A CN 103965363 A CN103965363 A CN 103965363A
- Authority
- CN
- China
- Prior art keywords
- extracellular region
- section
- immunoglobulin
- fusion rotein
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 title abstract description 24
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 title abstract description 24
- 108020001507 fusion proteins Proteins 0.000 title abstract description 6
- 102000037865 fusion proteins Human genes 0.000 title abstract description 6
- 108091026890 Coding region Proteins 0.000 title abstract description 4
- 101710089372 Programmed cell death protein 1 Proteins 0.000 title description 30
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 claims abstract description 20
- 239000003814 drug Substances 0.000 claims abstract description 7
- 230000004927 fusion Effects 0.000 claims description 73
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 61
- 210000004027 cell Anatomy 0.000 claims description 37
- 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 claims description 25
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 24
- 102000016844 Immunoglobulin-like domains Human genes 0.000 claims description 23
- 108050006430 Immunoglobulin-like domains Proteins 0.000 claims description 23
- 101100407308 Mus musculus Pdcd1lg2 gene Proteins 0.000 claims description 23
- 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 claims description 23
- 239000013612 plasmid Substances 0.000 claims description 20
- 206010028980 Neoplasm Diseases 0.000 claims description 19
- 102100033178 Vascular endothelial growth factor receptor 1 Human genes 0.000 claims description 15
- 108010076504 Protein Sorting Signals Proteins 0.000 claims description 13
- 108010053096 Vascular Endothelial Growth Factor Receptor-1 Proteins 0.000 claims description 13
- 230000014509 gene expression Effects 0.000 claims description 13
- 108091033319 polynucleotide Proteins 0.000 claims description 11
- 239000002157 polynucleotide Substances 0.000 claims description 11
- 102000040430 polynucleotide Human genes 0.000 claims description 11
- 239000000203 mixture Substances 0.000 claims description 10
- 206010033128 Ovarian cancer Diseases 0.000 claims description 9
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 9
- 201000007270 liver cancer Diseases 0.000 claims description 9
- 208000014018 liver neoplasm Diseases 0.000 claims description 9
- 239000013598 vector Substances 0.000 claims description 9
- 108060003951 Immunoglobulin Proteins 0.000 claims description 8
- 102000018358 immunoglobulin Human genes 0.000 claims description 8
- 239000013613 expression plasmid Substances 0.000 claims description 7
- 241000894006 Bacteria Species 0.000 claims description 5
- 206010006187 Breast cancer Diseases 0.000 claims description 4
- 208000026310 Breast neoplasm Diseases 0.000 claims description 4
- 206010009944 Colon cancer Diseases 0.000 claims description 4
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 4
- 210000004899 c-terminal region Anatomy 0.000 claims description 4
- 201000010989 colorectal carcinoma Diseases 0.000 claims description 4
- 210000003734 kidney Anatomy 0.000 claims description 4
- 201000005202 lung cancer Diseases 0.000 claims description 4
- 208000020816 lung neoplasm Diseases 0.000 claims description 4
- 201000001441 melanoma Diseases 0.000 claims description 4
- 208000017897 Carcinoma of esophagus Diseases 0.000 claims description 3
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 3
- 241000702421 Dependoparvovirus Species 0.000 claims description 3
- 241000233866 Fungi Species 0.000 claims description 3
- 201000003741 Gastrointestinal carcinoma Diseases 0.000 claims description 3
- 206010025323 Lymphomas Diseases 0.000 claims description 3
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 3
- 206010060862 Prostate cancer Diseases 0.000 claims description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 3
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 3
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 3
- 201000010881 cervical cancer Diseases 0.000 claims description 3
- 208000006990 cholangiocarcinoma Diseases 0.000 claims description 3
- 201000005619 esophageal carcinoma Diseases 0.000 claims description 3
- 208000021045 exocrine pancreatic carcinoma Diseases 0.000 claims description 3
- 201000010175 gallbladder cancer Diseases 0.000 claims description 3
- 201000007487 gallbladder carcinoma Diseases 0.000 claims description 3
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 3
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 3
- 201000002313 intestinal cancer Diseases 0.000 claims description 3
- 230000009465 prokaryotic expression Effects 0.000 claims description 3
- 201000000498 stomach carcinoma Diseases 0.000 claims description 3
- 241000701161 unidentified adenovirus Species 0.000 claims description 3
- 108700019146 Transgenes Proteins 0.000 claims description 2
- 239000002246 antineoplastic agent Substances 0.000 claims description 2
- 229940041181 antineoplastic drug Drugs 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 230000000968 intestinal effect Effects 0.000 claims description 2
- 239000002773 nucleotide Substances 0.000 claims description 2
- 125000003729 nucleotide group Chemical group 0.000 claims description 2
- 230000001225 therapeutic effect Effects 0.000 claims description 2
- 239000003981 vehicle Substances 0.000 claims description 2
- 210000001744 T-lymphocyte Anatomy 0.000 abstract description 16
- 210000004881 tumor cell Anatomy 0.000 abstract description 12
- 101000851018 Homo sapiens Vascular endothelial growth factor receptor 1 Proteins 0.000 abstract description 4
- 101001117312 Homo sapiens Programmed cell death 1 ligand 2 Proteins 0.000 abstract description 3
- 230000034994 death Effects 0.000 abstract description 3
- 230000002779 inactivation Effects 0.000 abstract description 3
- 230000004614 tumor growth Effects 0.000 abstract description 2
- 108010033276 Peptide Fragments Proteins 0.000 abstract 4
- 102000007079 Peptide Fragments Human genes 0.000 abstract 4
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 abstract 1
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 abstract 1
- 102000048119 human PDCD1LG2 Human genes 0.000 abstract 1
- 230000005909 tumor killing Effects 0.000 abstract 1
- 102100040678 Programmed cell death protein 1 Human genes 0.000 description 30
- 102000004196 processed proteins & peptides Human genes 0.000 description 17
- 230000000694 effects Effects 0.000 description 16
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 description 13
- 229920001184 polypeptide Polymers 0.000 description 13
- 125000000539 amino acid group Chemical group 0.000 description 12
- 108090000623 proteins and genes Proteins 0.000 description 12
- 238000001890 transfection Methods 0.000 description 9
- 108020004414 DNA Proteins 0.000 description 8
- 235000018102 proteins Nutrition 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 101100381481 Caenorhabditis elegans baz-2 gene Proteins 0.000 description 6
- 101100372762 Rattus norvegicus Flt1 gene Proteins 0.000 description 6
- 230000000259 anti-tumor effect Effects 0.000 description 6
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 description 5
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 5
- 239000013604 expression vector Substances 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 230000004913 activation Effects 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 239000012228 culture supernatant Substances 0.000 description 4
- 210000004405 cytokine-induced killer cell Anatomy 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 230000001900 immune effect Effects 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 108010074708 B7-H1 Antigen Proteins 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- 101000611936 Homo sapiens Programmed cell death protein 1 Proteins 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000010353 genetic engineering Methods 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 101001117317 Homo sapiens Programmed cell death 1 ligand 1 Proteins 0.000 description 2
- 101000808011 Homo sapiens Vascular endothelial growth factor A Proteins 0.000 description 2
- 239000012097 Lipofectamine 2000 Substances 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 101100519207 Mus musculus Pdcd1 gene Proteins 0.000 description 2
- 229930193140 Neomycin Natural products 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 239000002870 angiogenesis inducing agent Substances 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- PGBHMTALBVVCIT-VCIWKGPPSA-N framycetin Chemical compound N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CN)O2)N)O[C@@H]1CO PGBHMTALBVVCIT-VCIWKGPPSA-N 0.000 description 2
- 238000002523 gelfiltration Methods 0.000 description 2
- 102000048362 human PDCD1 Human genes 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 210000003292 kidney cell Anatomy 0.000 description 2
- 239000002105 nanoparticle Substances 0.000 description 2
- 229960004927 neomycin Drugs 0.000 description 2
- 229960003301 nivolumab Drugs 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 238000003259 recombinant expression Methods 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000012807 shake-flask culturing Methods 0.000 description 2
- 238000003153 stable transfection Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 101100372758 Danio rerio vegfaa gene Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 101000851007 Homo sapiens Vascular endothelial growth factor receptor 2 Proteins 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 230000033540 T cell apoptotic process Effects 0.000 description 1
- 102000009524 Vascular Endothelial Growth Factor A Human genes 0.000 description 1
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 1
- 102000016548 Vascular Endothelial Growth Factor Receptor-1 Human genes 0.000 description 1
- 102100039037 Vascular endothelial growth factor A Human genes 0.000 description 1
- 101150030763 Vegfa gene Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229940120638 avastin Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229960000397 bevacizumab Drugs 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000001728 clone cell Anatomy 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 102000058223 human VEGFA Human genes 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000031146 intracellular signal transduction Effects 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 230000004719 natural immunity Effects 0.000 description 1
- 238000011580 nude mouse model Methods 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000006337 proteolytic cleavage Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000452 restraining effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 208000000649 small cell carcinoma Diseases 0.000 description 1
- 229940043517 specific immunoglobulins Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000012096 transfection reagent Substances 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 230000005747 tumor angiogenesis Effects 0.000 description 1
- 230000004565 tumor cell growth Effects 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 230000004862 vasculogenesis Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Landscapes
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310046985.7A CN103965363B (zh) | 2013-02-06 | 2013-02-06 | 与pd-1和vegf高效结合的融合蛋白、其编码序列及用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310046985.7A CN103965363B (zh) | 2013-02-06 | 2013-02-06 | 与pd-1和vegf高效结合的融合蛋白、其编码序列及用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103965363A true CN103965363A (zh) | 2014-08-06 |
CN103965363B CN103965363B (zh) | 2021-01-15 |
Family
ID=51235406
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310046985.7A Active CN103965363B (zh) | 2013-02-06 | 2013-02-06 | 与pd-1和vegf高效结合的融合蛋白、其编码序列及用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103965363B (zh) |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105111314A (zh) * | 2015-08-13 | 2015-12-02 | 成都百世博生物技术有限公司 | 一种新型融合蛋白、药物组合物及其制备方法和用途 |
CN105601752A (zh) * | 2016-02-01 | 2016-05-25 | 长沙郝怡雅医药科技有限公司 | 一种多基因重组嵌合抗原受体分子 |
CN106832002A (zh) * | 2017-02-16 | 2017-06-13 | 上海科医联创生物科技有限公司 | 一种靶向pd‑1的融合蛋白及其相关应用 |
WO2017177908A1 (zh) * | 2016-04-11 | 2017-10-19 | 北京普纳生物科技有限公司 | Pd-l1和pd-l2重组蛋白及其用途 |
WO2017177907A1 (zh) * | 2016-04-11 | 2017-10-19 | 北京普纳生物科技有限公司 | 抗免疫检查点pd-l1和pd-l2肿瘤疫苗 |
CN107383174A (zh) * | 2017-08-21 | 2017-11-24 | 苏州立豪生物科技有限公司 | 一种能与pd‑1特异性结合的肿瘤抑制肽及其用途 |
WO2019062642A1 (zh) * | 2017-09-29 | 2019-04-04 | 北京比洋生物技术有限公司 | 靶向pd-1或pd-l1且靶向vegf家族的双靶向融合蛋白及其用途 |
CN114057883A (zh) * | 2020-07-31 | 2022-02-18 | 江苏恒瑞医药股份有限公司 | 双特异性抗原结合分子及其医药用途 |
WO2022042719A1 (zh) * | 2020-08-31 | 2022-03-03 | 普米斯生物技术(珠海)有限公司 | 抗vegf-抗pd-l1双特异性抗体、其药物组合物及用途 |
CN114133448A (zh) * | 2015-06-23 | 2022-03-04 | 纪念斯隆-凯特琳癌症中心 | 新型pd-1免疫调节剂 |
WO2023165516A1 (zh) * | 2022-03-02 | 2023-09-07 | 三优生物医药(上海)有限公司 | 抗pd-l1和vegf双特异性抗体及其应用 |
WO2024055995A1 (zh) * | 2022-09-14 | 2024-03-21 | 寻济生物科技(北京)有限公司 | 一种抗vegfa融合蛋白及其制备方法和应用 |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101213297A (zh) * | 2005-05-09 | 2008-07-02 | 小野药品工业株式会社 | 程序性死亡-1(pd-1)的人单克隆抗体及单独使用或与其它免疫治疗剂联合使用抗pd-1抗体来治疗癌症的方法 |
CN101522713A (zh) * | 2006-09-01 | 2009-09-02 | 津莫吉尼蒂克斯公司 | Il-31单克隆抗体的可变区序列和使用方法 |
CN101663323A (zh) * | 2006-12-27 | 2010-03-03 | 埃默里大学 | 用于治疗传染病和肿瘤的组合物和方法 |
CN101784564A (zh) * | 2007-07-13 | 2010-07-21 | 约翰霍普金斯大学 | B7-dc变体 |
CN102203125A (zh) * | 2008-08-25 | 2011-09-28 | 安普利穆尼股份有限公司 | Pd-1拮抗剂及其使用方法 |
CN102199216A (zh) * | 2000-04-28 | 2011-09-28 | 约翰霍普金斯大学 | 新的树突状细胞共刺激分子 |
CN102311502A (zh) * | 2010-07-10 | 2012-01-11 | 成都康弘生物科技有限公司 | 一种抑制血管新生或生长的融合蛋白及其医疗应用 |
CN102633883A (zh) * | 2012-02-24 | 2012-08-15 | 上海白泽生物科技有限公司 | 一种能与egfr、her2、vegf高效结合的融合蛋白、其编码序列及用途 |
-
2013
- 2013-02-06 CN CN201310046985.7A patent/CN103965363B/zh active Active
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102199216A (zh) * | 2000-04-28 | 2011-09-28 | 约翰霍普金斯大学 | 新的树突状细胞共刺激分子 |
CN101213297A (zh) * | 2005-05-09 | 2008-07-02 | 小野药品工业株式会社 | 程序性死亡-1(pd-1)的人单克隆抗体及单独使用或与其它免疫治疗剂联合使用抗pd-1抗体来治疗癌症的方法 |
CN101522713A (zh) * | 2006-09-01 | 2009-09-02 | 津莫吉尼蒂克斯公司 | Il-31单克隆抗体的可变区序列和使用方法 |
CN101663323A (zh) * | 2006-12-27 | 2010-03-03 | 埃默里大学 | 用于治疗传染病和肿瘤的组合物和方法 |
CN101784564A (zh) * | 2007-07-13 | 2010-07-21 | 约翰霍普金斯大学 | B7-dc变体 |
CN102203125A (zh) * | 2008-08-25 | 2011-09-28 | 安普利穆尼股份有限公司 | Pd-1拮抗剂及其使用方法 |
CN102311502A (zh) * | 2010-07-10 | 2012-01-11 | 成都康弘生物科技有限公司 | 一种抑制血管新生或生长的融合蛋白及其医疗应用 |
CN102633883A (zh) * | 2012-02-24 | 2012-08-15 | 上海白泽生物科技有限公司 | 一种能与egfr、her2、vegf高效结合的融合蛋白、其编码序列及用途 |
Non-Patent Citations (1)
Title |
---|
WANG W 等: "immunoglobulin heavy chain variable region [Homo sapiens]", 《GENBANK DATABASE》 * |
Cited By (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114133448A (zh) * | 2015-06-23 | 2022-03-04 | 纪念斯隆-凯特琳癌症中心 | 新型pd-1免疫调节剂 |
CN105111314B (zh) * | 2015-08-13 | 2019-01-08 | 成都百世博生物技术有限公司 | 一种新型融合蛋白、药物组合物及其制备方法和用途 |
CN105111314A (zh) * | 2015-08-13 | 2015-12-02 | 成都百世博生物技术有限公司 | 一种新型融合蛋白、药物组合物及其制备方法和用途 |
CN105601752B (zh) * | 2016-02-01 | 2019-08-23 | 海门郝怡雅医药科技有限公司 | 一种多基因重组嵌合抗原受体分子 |
CN105601752A (zh) * | 2016-02-01 | 2016-05-25 | 长沙郝怡雅医药科技有限公司 | 一种多基因重组嵌合抗原受体分子 |
WO2017177908A1 (zh) * | 2016-04-11 | 2017-10-19 | 北京普纳生物科技有限公司 | Pd-l1和pd-l2重组蛋白及其用途 |
WO2017177907A1 (zh) * | 2016-04-11 | 2017-10-19 | 北京普纳生物科技有限公司 | 抗免疫检查点pd-l1和pd-l2肿瘤疫苗 |
CN106832002A (zh) * | 2017-02-16 | 2017-06-13 | 上海科医联创生物科技有限公司 | 一种靶向pd‑1的融合蛋白及其相关应用 |
CN107383174A (zh) * | 2017-08-21 | 2017-11-24 | 苏州立豪生物科技有限公司 | 一种能与pd‑1特异性结合的肿瘤抑制肽及其用途 |
CN109575140A (zh) * | 2017-09-29 | 2019-04-05 | 北京比洋生物技术有限公司 | 靶向pd-1或pd-l1且靶向vegf家族的双靶向融合蛋白及其用途 |
CN109575140B (zh) * | 2017-09-29 | 2021-02-23 | 北京比洋生物技术有限公司 | 靶向pd-1或pd-l1且靶向vegf家族的双靶向融合蛋白及其用途 |
WO2019062642A1 (zh) * | 2017-09-29 | 2019-04-04 | 北京比洋生物技术有限公司 | 靶向pd-1或pd-l1且靶向vegf家族的双靶向融合蛋白及其用途 |
CN114057883A (zh) * | 2020-07-31 | 2022-02-18 | 江苏恒瑞医药股份有限公司 | 双特异性抗原结合分子及其医药用途 |
CN114057883B (zh) * | 2020-07-31 | 2024-04-16 | 江苏恒瑞医药股份有限公司 | 双特异性抗原结合分子及其医药用途 |
WO2022042719A1 (zh) * | 2020-08-31 | 2022-03-03 | 普米斯生物技术(珠海)有限公司 | 抗vegf-抗pd-l1双特异性抗体、其药物组合物及用途 |
WO2023165516A1 (zh) * | 2022-03-02 | 2023-09-07 | 三优生物医药(上海)有限公司 | 抗pd-l1和vegf双特异性抗体及其应用 |
WO2024055995A1 (zh) * | 2022-09-14 | 2024-03-21 | 寻济生物科技(北京)有限公司 | 一种抗vegfa融合蛋白及其制备方法和应用 |
Also Published As
Publication number | Publication date |
---|---|
CN103965363B (zh) | 2021-01-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7227290B2 (ja) | キメラ抗原受容体、組成物及び方法 | |
CN103965363A (zh) | 与pd-1和vegf高效结合的融合蛋白、其编码序列及用途 | |
JP7296367B2 (ja) | 二重特異性組換えタンパク質およびその応用 | |
US11292841B2 (en) | Anti-PD-1 nano-antibody and application thereof | |
JP7476298B2 (ja) | Mage-aに特異的に結合する抗原結合タンパク質 | |
US20220002418A1 (en) | Anti-pd-l1/vegf bifunctional antibody and use thereof | |
JP6599338B2 (ja) | Hbv感染および関連症状の治療のための免疫エフェクター細胞表面抗原およびhbv抗原結合性の二重特異性または多重特異性ポリペプチド | |
ES2433967T3 (es) | Productos de fusión anticuerpo-LIGHT como productos terapéuticos de cáncer | |
CN102633883B (zh) | 一种能与egfr、her2、vegf高效结合的融合蛋白、其编码序列及用途 | |
CN105330750A (zh) | 一种快速中止car-t细胞杀伤作用的分子刹车及其用途 | |
EA030147B1 (ru) | Биспецифические антигенсвязывающие молекулы, активирующие т-клетки | |
US20230203200A1 (en) | Recruiting agent further binding an mhc molecule | |
US9676858B2 (en) | Human bispecific EGFRvIII antibody and CD3 engaging molecules | |
CN108367070B (zh) | 免疫毒素与检查点抑制剂的组合治疗 | |
KR20220012856A (ko) | 항 pd―l1 항체 및 그의 용도 | |
CN109627340B (zh) | Cd3和prlr双特异性抗体及其构建与应用 | |
JP2021521817A (ja) | 新規な融合タンパク質およびこれを含む癌の予防または治療用薬学的組成物 | |
CN113817056A (zh) | 一种靶向cd70的单链抗体及其应用 | |
McCue et al. | Advances in modular control of CAR-T therapy with adapter-mediated CARs | |
CN114409797B (zh) | 重组抗体及其应用 | |
CN117999290A (zh) | 一种多特异性抗原结合蛋白及其应用 | |
CN109689691A (zh) | IFN-γ-诱导性调节T细胞可转化性抗癌(IRTCA)抗体及其应用 | |
KR20230006824A (ko) | Ige 항체를 포함하는 조성물 | |
JPWO2019209078A5 (zh) | ||
CN111484554A (zh) | 一种靶向4-1bb的肿瘤抑制性抗体及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20171117 Address after: Zhang Jiang Valley No. 780 building, 201203 Shanghai city Pudong New Area Cailun Road, room 723, Zhangjiang hi tech Applicant after: SHANGHAI ALLBRIGHT BIOTECH Co.,Ltd. Applicant after: SHANGHAI ENGINEERING RESEARCH CENTER FOR CELL THERAPY GROUP Co.,Ltd. Address before: Zhang Jiang Valley No. 780 building, 201203 Shanghai city Pudong New Area Cailun Road, room 723, Zhangjiang hi tech Applicant before: SHANGHAI ALLBRIGHT BIOTECH Co.,Ltd. |
|
CB02 | Change of applicant information | ||
CB02 | Change of applicant information |
Address after: Room 723, Zhangjiang Yaogu building, 780 Cailun Road, Zhangjiang hi tech, Pudong New Area, Shanghai 201203 Applicant after: SHANGHAI ALLBRIGHT BIOTECH Co.,Ltd. Applicant after: SHANGHAI CELL THERAPY GROUP Co.,Ltd. Address before: Room 723, Zhangjiang Yaogu building, 780 Cailun Road, Zhangjiang hi tech, Pudong New Area, Shanghai 201203 Applicant before: SHANGHAI ALLBRIGHT BIOTECH Co.,Ltd. Applicant before: SHANGHAI ENGINEERING RESEARCH CENTER FOR CELL THERAPY GROUP Co.,Ltd. |
|
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CP03 | Change of name, title or address | ||
CP03 | Change of name, title or address |
Address after: Room 723, Zhangjiang Yaogu building, 780 Cailun Road, Zhangjiang hi tech, Pudong New Area, Shanghai 201203 Patentee after: SHANGHAI ALLBRIGHT BIOTECH Co.,Ltd. Country or region after: China Patentee after: Shanghai Cell Therapy Group Co.,Ltd. Address before: Room 723, Zhangjiang Yaogu building, 780 Cailun Road, Zhangjiang hi tech, Pudong New Area, Shanghai 201203 Patentee before: SHANGHAI ALLBRIGHT BIOTECH Co.,Ltd. Country or region before: China Patentee before: SHANGHAI CELL THERAPY GROUP Co.,Ltd. |